(Press-News.org) Geneva, Switzerland: Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.
In two presentations today (Saturday) and tomorrow (Sunday) researchers will tell the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO) that image-guided brachytherapy is able to deliver very high doses, which prevent the tumour from growing in over 90% of patients, with few serious side-effects.
One of the problems with radiotherapy for cervical cancer is that the vagina receives a high dose of radiotherapy, which can cause symptoms such as vaginal dryness, vaginal narrowing and shortening, with a loss of flexibility (stenosis), vaginal inflammation (mucositis), bleeding, or a hole in the wall of the vagina (vaginal fistula) – one of the most serious but rare complications. The bowel and bladder can also be affected by radiotherapy for cervical cancer.
Image-guided brachytherapy involves delivering radiotherapy to the tumour by placing a radioactive source in an applicator, positioned internally in the tumour region. Imaging, either by repeated computer tomography (CT) scans or preferably magnetic resonance imaging (MRI), is used at the time of brachytherapy in order to delineate both the tumour and organs at risk in relation the applicator. This enables radiation oncologists to measure and evaluate the tumour response to the treatment, and adjust the dose accordingly, while sparing surrounding organs. [1]
However, until now, there have been few studies investigating the relationship between the dose of radiotherapy and the effects it has on the vagina during brachytherapy for cervical cancer, according to Ms Kathrin Kirchheiner (MSc), who will be reporting on the international, multi-centre prospective clinical trial EMBRACE (European and international study on MRI-guided brachytherapy in locally advanced cervical cancer) at the meeting today (Saturday).
"To date, the EMBRACE study has followed 523 patients in 19 centres for an average of 14 months to establish a benchmark for clinical outcome with regard to control of the tumour's growth, patient survival, adverse effects of treatment and quality of life," said Ms Kirchheiner, who is a PhD student in the Department of Radiotherapy at the Medical University Vienna (Austria). [1]
Patients with cervical cancer that had started to spread from the original site to nearby tissues and lymph nodes (locally advanced cancer) underwent external beam radiotherapy, chemotherapy and MRI-guided brachytherapy. The vagina and the effects of the treatment on it (morbidity) were assessed at the start of treatment, every three months afterwards for the first year, once every six months in the second and third year, and annually thereafter. MRI was used to assess the amount of dose being delivered to the upper part of the vaginal wall.
"Our results show that severe vaginal side-effects are rare," said Ms Kirchheiner. "The majority of patients are likely to experience mild to moderate (grade 1 or 2) vaginal morbidity in the first two years after the end of treatment. The most frequently reported symptom is vaginal shortening and narrowing in the upper vagina. We performed a dose response analysis to measure the relationship between the amount of dose delivered to the upper vaginal wall and the probability of vaginal morbidity and found that with increasing dose to this region, the probability for moderate vaginal morbidity increases significantly."
This is the first time that the occurrence of mild and moderate side-effects on the vagina have been systematically recorded and related to the amount of radiation dose in this way. "This is important for patients because studies on their quality of life have shown that mild and moderate vaginal symptoms and associated sexual dysfunction can cause long-term distress in cervical cancer survivors, but until now a clear dose response relationship had not been established.
"Brachytherapy is an essential part of the curative treatment of locally advanced cervical cancer, because of the high dose that can be delivered to the tumour while sparing organs at risk of damage from the treatment. With the possibility of dose adaptation and optimisation in image guided adaptive brachytherapy, a highly individualised and tailored treatment has become possible, comparable to the targeted, personalised therapies in medical oncology," concluded Ms Kirchheiner.
The second study is retro-EMBRACE, which collected data on 592 patients in 12 institutions in Europe and Asia. Associate Professor Kari Tanderup, of the Department of Oncology at Aarhus University Hospital, Denmark, will be reporting results from this retrospective study tomorrow (Sunday).
"When using radiotherapy to treat cervical cancer there is a certain distribution of absorbed dose within the body and it is essential to know the dose level needed for local control of the tumour. However, there has been a wide range of brachytherapy schedules throughout the world with application of different dose levels for cervical cancer, and there has been limited evidence for a clearly defined dose response relationship," she will say.
"One of the reasons is that most cervical cancer brachytherapy experience has been based on planning on radiographs and not 3D imaging. With radiographs it is difficult to assess the dose to the tumour precisely, whereas with MRI or CT guided brachytherapy is it now possible to assess the dose to the tumour with much higher precision. With the retroEMBRACE study it has been possible for the first time to assess a dose response relationship in a large number of patients in a multicentre setting. We looked at different dose levels and found a significant increase in local control with higher doses."
Cervical cancer patients were treated with external beam radiotherapy, chemotherapy and image-guided adaptive brachytherapy (IGABT) based on MRI or CT scans. The amount of residual tumour (known as "high risk clinical tumour volume" or HR CTV) was assessed after the external beam radiotherapy in order to plan IGABT, and to target the residual tumour. "By taking the residual tumour into account we are able to tailor the brachytherapy dose to the individual patient and to the individual tumour response. We call this 'adaptive radiotherapy' because we adapt our treatment to changes which occur during radiochemotherapy," explains Prof Tanderup.
"Our study shows very clearly that the higher the dose the better the tumour's response to the brachytherapy for the entire patient population. It is possible to obtain local control in over 90 percent of patients with application of very high doses of over 90Gy. Brachytherapy is a very appropriate technique to obtain highly focused boost doses, and retroEMBRACE shows that it is actually possible to deliver doses greater than 90Gy for a significant fraction of the patients. It would not be possible to achieve doses greater than 90Gy with external beam radiotherapy without significantly increasing dose to critical organs, and therefore brachytherapy is a crucial component of radiotherapy in cervix cancer. Furthermore, the study also enables us to analyse results in patients with different risks of their tumours recurring or continuing to grow."
She will conclude: "The retroEMBRACE study is important for the community because it establishes evidence for a dose response relationship in locally advanced cervical cancer; it shows that local control in over 90 percent of patients can be obtained with the use of MRI-guided brachytherapy; retroEMBRACE makes it possible for institutions to change their dose prescription in order to optimise the balance between local control and adverse side-effects; and it demonstrates that the adaptive target concept which has been developed for MRI-guided brachytherapy is robust in a multicentre setting."
President of ESTRO, Professor Vincenzo Valentini, a radiation oncologist at the Policlinico Universitario A. Gemelli, Rome, Italy, commented: "This is a tangible example of how large series of data, collected by collaborative networks, and high quality treatment that takes advantage of the latest advances in imaging, can help radiation oncologists to adapt treatments to individual patients so as to give them the best chance of a cure with fewer side-effects."
###
[1] Brachytherapy, where the radiation source is placed inside the body, differs from external beam radiotherapy, where the radiation is delivered from outside the body using linear accelerators.
[2] EMBRACE recruited patients from centres in Europe, North America and India. Retro-EMBRACE looked at data from patients from Austria, Denmark, France, The Netherlands, UK, Slovenia, Thailand and Ireland.
[3] EMBRACE was sponsored by the Medical University of Vienna, and funded by Nucletron (an Elekta company) and Varian Medical Systems. Retro-EMBRACE was supported by funding from Nucletron (an Elekta company) and Varian Medical Systems.
2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
2013-04-20
ELSE PRESS RELEASES FROM THIS DATE:
Calculating tsunami risk for the US East Coast
2013-04-20
Salt Lake City, Utah – The greatest threat of a tsunami for the U.S. east coast from a nearby offshore earthquake stretches from the coast of New England to New Jersey, according to John Ebel of Boston College, who presented his findings today at the Seismological Society of America 2013 Annual Meeting.
The potential for an East Coast tsunami has come under greater scrutiny after a 2012 earthquake swarm that occurred offshore about 280 kilometers (170 miles) east of Boston. The largest earthquake in the 15-earthquake swarm, most of which occurred on April 12, 2012, ...
A global murmur, then unusual silence
2013-04-20
SALT LAKE CITY, UTAH -- In the global aftershock zone that followed the major April 2012 Indian Ocean earthquake, seismologists noticed an unusual pattern. The magnitude (M) 8.6 earthquake, a strike-slip event at intraoceanic tectonic plates, caused global seismic rates of M≥4.5 to rise for several days, even at distances thousands of kilometers from the mainshock site. However, the rate of M≥6.5 seismic activity subsequently dropped to zero for the next 95 days.
This period of quiet, without a large quake, has been a rare event in the past century. So why ...
Intense, specialized training in young athletes linked to serious overuse injuries
2013-04-20
MAYWOOD, Il. - Young athletes who specialize in one sport and train intensively have a significantly higher risk of stress fractures and other severe overuse injuries, even when compared with other injured athletes, according to the largest clinical study of its kind.
For example, young athletes who spent more hours per week than their age playing one sport – such as a 12-year-old who plays tennis 13 or more hours a week – were 70 percent more likely to experience serious overuse injuries than other injuries.
Loyola University Medical Center sports medicine physician ...
Mathematical models out-perform doctors in predicting cancer patients' responses to treatment
2013-04-20
Geneva, Switzerland: Mathematical prediction models are better than doctors at predicting the outcomes and responses of lung cancer patients to treatment, according to new research presented today (Saturday) at the 2nd Forum of the European Society for Radiotherapy and Oncology (ESTRO).
These differences apply even after the doctor has seen the patient, which can provide extra information, and knows what the treatment plan and radiation dose will be.
"The number of treatment options available for lung cancer patients are increasing, as well as the amount of information ...
Breast pain issue for 1 in 3 female marathon runners
2013-04-20
Women with larger cup sizes seem to be more susceptible, but childless women also seem to be more prone, and wearing a sports bra doesn't always help, finds the study, which publishes as London gears up for its annual international marathon tomorrow (Sunday April 21).
The authors base their findings on the responses of just under 1300 female competitors passing through the registration zone for last year's marathon in the capital.
The women were asked how much exercise they took, and its intensity - including participation in marathons - whether they wore sports bras ...
Painkillers taken before marathons linked to potentially serious side effects
2013-04-20
Many competitors try to prevent pain interfering with their performance by taking painkillers that are readily available in pharmacies and supermarkets, say the authors.
And in a bid to find out what impact these common drugs might have, the authors quizzed participants in the 2010 Bonn Marathon/Half-Marathon about their use of medication and any symptoms they had during and/or after the race.
In all, just under 4000 (56%) of all 7048 competitors returned their online questionnaires. Most (87%) had run marathons before.
Of those who took painkillers before the race, ...
UCLA study finds scientific basis for cognitive complaints of breast cancer patients
2013-04-20
For many years, breast cancer patients have reported experiencing difficulties with memory, concentration and other cognitive functions following cancer treatment. Whether this mental "fogginess" is psychosomatic or reflects underlying changes in brain function has been a bone of contention among scientists and physicians.
Now, a new study led by Dr. Patricia Ganz, director of cancer prevention and control research at UCLA's Jonsson Comprehensive Cancer Center, demonstrates a significant correlation between poorer performance on neuropsychological tests and memory complaints ...
Ultrafast technique unlocks design principles of quantum biology
2013-04-20
University of Chicago researchers have created a synthetic compound that mimics the complex quantum dynamics observed in photosynthesis and may enable fundamentally new routes to creating solar-energy technologies. Engineering quantum effects into synthetic light-harvesting devices is not only possible, but also easier than anyone expected, the researchers report in the April 18 edition of Science Express.
The researchers have engineered small molecules that support long-lived quantum coherences. Coherences are the macroscopically observable behavior of quantum superpositions. ...
Nitrogen has key role in estimating CO2 emissions from land use change
2013-04-20
CHAMPAIGN, Ill. — A new global-scale modeling study that takes into account nitrogen – a key nutrient for plants – estimates that carbon emissions from human activities on land were 40 percent higher in the 1990s than in studies that did not account for nitrogen.
Researchers at the University of Illinois at Urbana-Champaign and the University of Bristol Cabot Institute published their findings in the journal Global Change Biology. The findings will be a part of the upcoming Fifth Assessment Report from the Intergovernmental Panel on Climate Change.
"One nutrient can ...
UTSW researchers identify new potential target for cancer therapy
2013-04-20
DALLAS – April 22, 2013 – Researchers at UT Southwestern Medical Center have found that alternative splicing – a process that allows a single gene to code for multiple proteins – appears to be a new potential target for anti-telomerase cancer therapy.
The enzyme telomerase is overexpressed in almost all cancer cells, and previous research efforts have failed to identify good telomerase inhibitors. The study by Dr. Woodring Wright and UT Southwestern colleagues in the April 4 issue of Cell Reports identifies a new approach for inhibiting telomerase, which is an enzyme ...